Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CRISPR-Cas9-LNP
- Development stage
- Preclinical
- Lead developer
- InhaTarget Therapeutics
- Modality
- CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Inhalation
01
Overview
CRISPR-Cas9-LNP is a research-stage, inhaled gene-editing therapeutic candidate being developed by InhaTarget Therapeutics for the treatment of squamous non-small cell lung cancer (NSCLC). The therapeutic approach utilizes lipid nanoparticles (LNPs) to deliver CRISPR-Cas9 gene-editing machinery directly to the lungs via inhalation. This localized delivery method is designed to target and reprogram tumor-associated macrophages (TAMs) or directly target tumor cells, bypassing systemic toxicities associated with intravenous administration. While the specific gene target for this program has not been publicly disclosed, the platform aims to modulate the tumor microenvironment to overcome treatment resistance and inhibit tumor progression.
02
Targets
DNA
Beyond the preview
Go deeper on CRISPR-Cas9-LNP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CRISPR-Cas9-LNP.